The surviving rats were randomly assigned to one of two treatment groups: the paricalcitol group (n = 8), which was injected intraperitoneally with paricalcitol (Zemplar; Abbott Laboratories, Abbott Park, IL) (1 μg/kg), and the normal saline group (n = 8), which was injected intraperitoneally with an equivalent volume of normal saline. A previous study showed that a low dose of calcitriol (1 μg/kg) reduced HIBI in a rat model of transient middle cerebral artery occlusion [12 (link)]. Therefore, we chose to use the low dose of 1 μg/kg to avoid potential side effects such as hypercalcemia and hyperphosphatemia. After recovery of the righting reflex, rats were returned to their cages and observed until 4 days after cerebral ischemia. During the observational period, we injected paricalcitol (1 μg/kg) intraperitoneally, or an equivalent volume of normal saline in the control group, on days 1, 2, and 3 post-ischemia.
Zemplar
Manufactured by Abbott
Zemplar is a laboratory product manufactured by Abbott. It is a parenteral vitamin D analogue used in the management of secondary hyperparathyroidism in patients with chronic kidney disease.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using zemplar
1
Neuroprotective Effects of Paricalcitol in Ischemic Stroke
2
Paricalcitol Neuroprotection in Cerebral Ischemia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Surviving rats were randomly assigned to one of the two treatment groups: paricalcitol group (n = 8), injected intraperitoneally with paricalcitol (Zemplar; Abbott Laboratories, Abbott Park, IL) (1 μg/kg); and normal saline group (n = 8), injected intraperitoneally with an equivalent volume of normal saline. We administered drugs 5 min after the end of the ischemic period. After recovery of righting re ex, rats were returned to the cages and observed until four days after cerebral ischemia. During the observational period, we intraperitoneally injected paricalcitol (1 μg/kg) or an equivalent volume of normal saline on days 1, 2 and 3 post-ischemia.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!